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A 62-year-old man presented with progressive exertional dyspnea and angina. His past medical history is notable for coronary artery disease, for which he underwent a coronary artery bypass graft surgery 8 years earlier. A few years afterward, he underwent aortic valve (AV) bypass (AVB) surgery for severe aortic stenosis (AS) using an apicoaortic conduit to the descending aorta consisting of a 16-mm connector and an 18-mm valved conduit (Hancock valve; Medtronic, Minneapolis, MN; Figures 1 and 2 ; onlineonly Data Supplement Movie I). After a period of initial improvement in symptoms, the patient developed progressive dyspnea and angina and was referred for additional cardiac workup.
The patient underwent a bicycle ergometer test, which showed a diminished functional capacity and was stopped because of fatigue and a hypotensive response. He underwent a 2-dimensional transthoracic echocardiogram with gradual dobutamine infusion. He was found to have a heavily calcified AV (online-only Data Supplement Movie II) with a rest mean transvalvular gradient of 34 mm Hg and velocity of 3.5 m/s, which increased to 50 mm Hg and 4.8 m/s, respectively, at peak dobutamine dose ( Figure 3 ). This corresponded with a flow increase across the native AV from 1.7 to 4.3 L/min. A minimal mean gradient of 2 mm Hg was detected at the apicoaortic conduit proximal limb at the anastomosis of the left ventricular (LV) apex and conduit, which increased to 3.4
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With Severe Aortic Stenosis (Figure 4 ; online-only Data Supplement Movies III and IV). A mean gradient of 38 mm Hg across the heavily calcified native AV was detected using a double-lumen catheter. On selective catheterization of the distal portion of the apicoaortic conduit (distal to the prosthetic Hancock AV inside the conduit) using an end-hole catheter, a gradient between the LV and distal limb of the apicoaortic conduit of 12 mm Hg was evident. A slow pullback of the end-hole catheter from the distal limb of the apicoaortic conduit into the aorta, with intermittent contrast angiography, showed an 80% narrowing at the conduitaorta anastomosis, and a 40-mm Hg gradient between the distal limb of the apicoaortic conduit and the aorta at the anastomosis site ( Figure 5 ; online-only Data Supplement Movie V). An ECG-gated contrast-enhanced computed tomography scan showed heavy AV calcification and an aortic annulus area of 489 mm 2 . The apicoaortic conduit was noted from the LV apex to the descending aorta, with severe narrowing at the distal anastomotic site ( Figure 6 ). The patient's calculated STS score put him at 9.4% mortality risk and 38.6% risk of morbidity or mortality for redo AVR. After deliberations by our multidisciplinary heart team, he underwent a successful transfemoral transcatheter AV replacement (TAVR) using an Edwards Sapien 26-mm valve (Edwards Lifesciences LLC, Irvine, CA; online-only Data Supplement Movies VI and VII). Four months afterward, he reported marked improvement in his functional capacity and symptoms. A repeat transthoracic echocardiogram demonstrated a well-seated bioprosthetic valve with a mean gradient of <2 mm Hg, no aortic insufficiency, and very minimal flow across the conduit. AVB surgery relieves AS by shunting blood from the LV apex to the descending thoracic aorta through a valved conduit and represents an important therapeutic option for highrisk patients with symptomatic AS. 1 AVB surgery was first reported in animal models in 1955, but the first successful clinical case was done in 1962. Although it was subsequently eclipsed by conventional AVR, the continued improvements in technology and surgical technique have contributed to its Jneid et al TAVR/Apicoaortic Conduit Obstruction/AS e493 resurgence, especially with the realization that AVB surgery can be performed without median sternotomy or cardiopulmonary bypass, has low rates of stroke and renal dysfunction, and is durable with infrequent late conduit obstruction. 2 TAVR was approved in the United States by the US Food and Drug Administration in November 2011 in patients with severe AS, after it was shown superior to standard therapy in inoperable patients 3 and comparable to surgical AVR in patients with high surgical risk. 4 The construction of an AVB conduit usually results in a predictable distribution of the stroke volume between the native stenotic LV outflow tract and the conduit. In a series of 47 high-risk AS patients treated with AVB surgery (2003-2009), relative conduit flow represented 68±8% of the total cardiac output at midterm follow-up. 2 In our patient, the flow across the conduit represented only 58% of the total cardiac output and was reduced to 52% at peak dobutamine, raising suspicion for conduit obstruction, which was confirmed and localized to the aorta-conduit anastomosis site during simultaneous left heart and conduit catheterization. Interestingly, the cardiac output across the Edwards Sapien valve accounted for >90% of the total cardiac output, speaking for the marked efficacy of this procedure. To our knowledge, this is the first report in the literature of a patient undergoing TAVR after AVB. 
